Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 2/3 1

Status

Terminated 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 2

Conditions

Neurofibromatosis 2 2Neuroma, Acoustic 1Neurilemmoma 1Meningioma 1

Interventions

HDAC-42 2Bevacizumab 2temsirolimus 1neratinib 1brigatinib 1Valproic Acid 1Sirolimus 1Immunoglobulin G 1Doxycycline 1Disulfides 1Crizotinib 1Cetuximab 1Aspirin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Neurofibromatosis 2 × HDAC-42 × 1 year × Clear all
NCT02282917 2025-12-05

Exploratory Evaluation of AR-42 Histone Deacetylase Inhibitor in the Treatment of Vestibular Schwannoma and Meningioma

Massachusetts Eye and Ear Infirmary

Phase EARLY_PHASE1 Terminated
7 enrolled 19 charts
CNS

Meningioma, Neurilemmoma, Neuroma, Acoustic, Neurofibromatosis 2

NCT05130866 2025-10-07

POPLAR-NF2

Recursion Pharmaceuticals Inc.

Phase 2/3 Terminated
25 enrolled
CNS

Neurofibromatosis 2

Data powered by HemOnc (CC BY 4.0) Colophon âš¡